Skip to main content
. Author manuscript; available in PMC: 2015 Mar 23.
Published in final edited form as: Chin Clin Oncol. 2014 Jun 9;3(4):49. doi: 10.3978/j.issn.2304-3865.2014.06.04

Figure 2.

Figure 2

Diagrams of the marker-stratified design. Equal randomized marker-stratified design has a fixed 1:1 randomization ratio throughout the trial to assign patients into the targeted therapy and the standard therapy, respectively. On the other hand, the randomization ratio for the Bayesian adaptive randomized marker-stratified design varies during the trial. As illustrated, the randomization ratio in the marker positive group could change from 1:1 to 2:1 and to 3:1 while, in the marker negative group, they could change from 1:1 to 1:2 to 1:3 assuming that the targeted therapy is more effective for the marker positive patients and the standard therapy is more effective for the marker negative patients.